|
|
|
Volumn 22, Issue 1, 2007, Pages 14-
|
|
Talactoferrin alpha receives fast-track designation for the treatment of non-small cell lung cancer.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
LACTOFERRIN;
PLACEBO;
RECOMBINANT PROTEIN;
TALACTOFERRIN ALFA;
UNCLASSIFIED DRUG;
ARTICLE;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
DRUG APPROVAL;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
LEGAL ASPECT;
LUNG NON SMALL CELL CANCER;
LUNG TUMOR;
ORAL DRUG ADMINISTRATION;
PHASE 2 CLINICAL TRIAL;
RANDOMIZED CONTROLLED TRIAL;
SURVIVAL RATE;
UNITED STATES;
ADMINISTRATION, ORAL;
ANTINEOPLASTIC AGENTS;
CARCINOMA, NON-SMALL-CELL LUNG;
CLINICAL TRIALS, PHASE II;
DRUG APPROVAL;
HUMANS;
LACTOFERRIN;
LUNG NEOPLASMS;
PLACEBOS;
RANDOMIZED CONTROLLED TRIALS;
RECOMBINANT PROTEINS;
SURVIVAL RATE;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 34247859296
PISSN: 19351623
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (6)
|
|
References (0)
|
